Insider Selling: Liquidia Co. (NASDAQ:LQDA) CEO Sells 8,360 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,360 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $121,888.80. Following the completion of the sale, the chief executive officer now owns 826,985 shares of the company’s stock, valued at $12,057,441.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Roger Jeffs also recently made the following trade(s):

• On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $452,183.06.

Liquidia Trading Up 1.2 %

Shares of LQDA traded up $0.16 during trading hours on Wednesday, hitting $13.74. 426,187 shares of the stock traded hands, compared to its average volume of 943,607. Liquidia Co. has a 1-year low of $5.71 and a 1-year high of $16.99. The firm has a market capitalization of $1.04 billion, a PE ratio of -11.27 and a beta of 0.16. The business has a fifty day moving average of $14.77 and a 200-day moving average of $10.88.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The firm had revenue of $4.53 million for the quarter, compared to analyst estimates of $5.29 million. As a group, equities research analysts expect that Liquidia Co. will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently added to or reduced their stakes in LQDA. Vanguard Group Inc. raised its position in shares of Liquidia by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company’s stock worth $34,212,000 after purchasing an additional 69,524 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Liquidia during the fourth quarter worth about $849,000. Price T Rowe Associates Inc. MD raised its position in shares of Liquidia by 9.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after purchasing an additional 989 shares during the period. Bluefin Capital Management LLC bought a new position in shares of Liquidia during the fourth quarter worth about $302,000. Finally, Barclays PLC raised its position in Liquidia by 1,105.2% in the 4th quarter. Barclays PLC now owns 103,021 shares of the company’s stock valued at $1,239,000 after buying an additional 94,473 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Liquidia in a report on Wednesday, April 10th. HC Wainwright boosted their price objective on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 14th. Wedbush restated an “underperform” rating and set a $3.00 price objective on shares of Liquidia in a research report on Thursday, December 21st. LADENBURG THALM/SH SH boosted their price objective on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, Bank of America upped their price target on Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).